Cytosorbents Corp
cytosorbents.comWhat Do They Do?
Sells blood-purification cartridges and pumps to hospitals treating critically ill and cardiac-surgery patients, organ-transplant teams, and veterinary care providers.
10-K for FY2025, filed Mar 30, 2026CytoSorbents’ technology platform centers on hemocompatible, highly porous polymer beads that act like tiny sponges to remove harmful…View ↗
CytoSorb is an extracorporeal blood purification cartridge that is approved in the European Union and distributed in more than 70 countries…View ↗
ECOS-300CY is approved in the E.U. to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system…View ↗
VetResQ is a broad-spectrum blood purification adsorber commercially available in the U.S. animal health market to help treat drug…View ↗
PuriFi is an E.U. Medical Device Regulation (MDR) approved advanced hemoperfusion pump that we co-developed with our original equipment…View ↗
How Do They Make Money?
Hospitals and distributors or strategic partners buy devices and accessory parts, with product sales counted when the products ship. U.S. government agencies also fund work under grant contracts.
10-K for FY2025, filed Mar 30, 2026Revenue is typically recognized when the Company ships its products to its direct customers and distributors/strategic partners. The amount…View ↗
The performance obligations in contracts with direct customers and distributors/strategic partners are for the shipment of the CytoSorb…View ↗
A significant portion of our revenues are from product sales in Germany. All of our grant receipts are from government agencies in the…View ↗
$37.1M
-
10-K for FY2025, filed Mar 30, 2026
$37.1M ↗
Who Are Their Customers?
Hospitals in Germany and other markets order directly, while distributors and strategic partners serve other countries. Direct orders are shipped to customers from the Berlin warehouse.
10-K for FY2025, filed Mar 30, 2026
Do Revenues Turn Into Profits?
No. It lost $8.2M in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$14.7MView ↗
10-K for FY2025, filed Mar 30, 2026
−$8.2MView ↗
10-K for FY2025, filed Mar 30, 2026
−$12.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$4.4MView ↗
- ▼ Now a loss
- vs $1.9M in Q2 FY2025
-
Jul 6, 2026
Nasdaq warned of a market-value listing-rule failure
The company has until December 28, 2026, to regain compliance; the notice did not itself delist its stock.
Sources
8-K, filed Jul 6, 2026
On June 29, 2026, CytoSorbents Corporation, a Delaware corporation (the “Company”), received a written notice (“Notice”) from the Listing…View ↗
-
Apr 2, 2026
Nasdaq extended time to meet its minimum bid-price rule
The extension runs through September 28, 2026; the notice had no immediate effect on the stock's listing.
Sources
8-K, filed Apr 2, 2026
On April 1, 2026, CytoSorbents Corporation, a Delaware corporation (the “Company”), received a letter (the “Extension Notice”) from the…View ↗
Shrinking. Revenue fell 14% in 4 years, from $43.2M in FY2021 to $37.1M in FY2025, about 4% a year.
Broader direct-sales reach
The older report described direct sales in Poland, the Netherlands, and Nordic countries; the latest report also describes direct sales in India and a Dubai sales subsidiary serving as a gateway to the Middle East and Africa.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 30, 2026On March 5, 2019, the Company announced the expansion of direct sales of CytoSorb for all applications to Poland and the Netherlands, and…View ↗
Company established CytoSorbents Poland Sp. z.o.o. In March 2022, the Company formed CytoSorbents Medical UK Limited to provide marketing…View ↗
Who Do They Compete With?
Competes with Vantive, Toray, Jafron, Efferon, Fresenius Medical Care, and Aimalojic
10-K for FY2025, filed Mar 30, 2026CytoSorb: CytoSorb is a hemoperfusion cartridge, using an adsorbent of specified pore range, which controls the size of the molecules which…View ↗
Loading...
